首页> 外国专利> method for producing amp; amp; uarr; 1 amp; amp; uarr; amp; amp; uarr; 3 amp; amp; uarr; amp; amp; uarr; 1 amp; amp; uarr; j - radio toluidinblau and amp; amp; uarr; 1 amp; amp; uarr; amp; amp; uarr; 2 amp; amp; uarr; amp; amp; uarr; 5 amp; amp; uarr; j - radio toluidinblau

method for producing amp; amp; uarr; 1 amp; amp; uarr; amp; amp; uarr; 3 amp; amp; uarr; amp; amp; uarr; 1 amp; amp; uarr; j - radio toluidinblau and amp; amp; uarr; 1 amp; amp; uarr; amp; amp; uarr; 2 amp; amp; uarr; amp; amp; uarr; 5 amp; amp; uarr; j - radio toluidinblau

机译:生产方法ua 1和ua & ua 3& ua & ua 1和ua j-托莱丁布劳广播电台和& ua 1和ua & ua 2和ua & ua 5和ua j-托莱丁布劳广播电台

摘要

A new process is claimed for the production of 131I-toluidine blue (Ia) and 125-I toluidine blue (Ib) 20mg o-toluidine blue is dissolved in 1ml distilled water by shaking 5 mins. in a vortex mixer. The solution is filtered through a 0.22 mu membrane filter into a sterile penicillin vial and the filter is rinsed with 2 x 0.5ml distilled water; 321mg KIO3 and 479mg KI are dissolved in 100ml distilled water and the solution is filtered through a 0.22 mu membrane filter, and 0.5ml of the resulting sterile KIO3/KI solution are taken up in a sterile syringe. An air cannula is inserted through the rubber stopper of the penicillin vial, 5 mCi 131I or 125I (in a volume of 0.05-0.1 ml; specific activity pref. ca 200 mCi/ml; free from reducing substances) are taken up in a sterile syringe and added to the o-toluidine blue solution, the radioactive vials being rinsed with 0.5 ml distilled water. o-Toluidine blue and radioiodine are mixed ca 30 seconds on a vortex mixer; 0.5ml KIO3/KI is added from the syringe and likewise mixed 30 seconds. 1 drop of 25% HCl is carefully added, then the air cannula is removed from the penicillin vial and the solution mixed 5 mins. on the vortex mixer. After 24-hr. incubation (when 95% plus-or-minus 2%, a pH of 7.4-7.5, and an in-vitro stability of over 4 months. (Ia) and (Ib) are useful as radiodiagnostic agents for the scintigraphy of parenchymal organs, the parathyroid and the pancreas. The new process gives (Ia) and (Ib) in high yields. The products are of high purity, stability, specific activity and radiochemical purity. The process uses small volumes of liquids.
机译:要求保护生产131I-甲苯胺蓝(Ia)和125I-甲苯胺蓝(Ib)的新方法,通过摇动5分钟将20mg邻甲苯胺蓝溶解在1ml蒸馏水中。在涡旋混合器中。将该溶液通过0.22μm的膜滤器过滤到无菌的青霉素小瓶中,并用2×0.5ml的蒸馏水冲洗该滤器。将321mg KIO3和479mg KI溶于100ml蒸馏水中,并通过0.22μm的膜滤器过滤该溶液,并将0.5ml所得的无菌KIO3 / KI溶液吸收在无菌注射器中。将空气套管插入青霉素小瓶的橡胶塞中,将5 mCi 131I或125I(体积为0.05-0.1 ml;比活性优选为约200 mCi / ml;不含还原性物质)无菌包装。注射器并加入邻甲苯胺蓝溶液中,用0.5毫升蒸馏水冲洗放射性小瓶。将邻甲苯胺蓝和放射性碘在涡旋混合器上混合约30秒。从注射器中加入0.5ml KIO3 / KI,同样混合30秒。小心地加入1滴25%HCl,然后从青霉素瓶中取出空气套管,将溶液混合5分钟。在涡旋混合器上。 24小时后。孵育(当95%正负2%,pH值为7.4-7.5且体外稳定性超过4个月时。(Ia)和(Ib)可用作薄壁器官闪烁显像的放射诊断剂,新工艺可以高收率地生产(Ia)和(Ib),产品具有高纯度,稳定性,比活度和放射化学纯度,该工艺使用少量液体。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号